REPLIGEN acquisition history

Acquisition of the bioprocessing business of Novozymes Biopharma Sweden AB, a supplier of cell-culture growth factors and other products used in the manufacture of biologic drugs. Repligen called it a transformative deal that elevated the company to a world-leading supplier of products for manufacturing biologic drugs and accelerated its path to sustainable profitability. ~$22.7 million (EUR 17 million) cash + up to EUR 4 million (~$5.6M) milestones.

This acquisition positions Repligen as a leading producer of high value, consumable products that will directly benefit from the long-term growth of the biologics market. Earlier this year we announced our strategic objective to transition into a commercially focused company, and the acquisition of the Novozymes business will deliver on that goal.Walter C. Herlihy — President and CEO, Repligen Corporation

Acquisition of Refine Technology's business, centered on the market-leading ATF (Alternating Tangential Flow) System used by biopharmaceutical manufacturers for perfusion cell culture. Repligen called it a significant step toward building a best-in-class bioprocessing company. ~$24.5 million upfront ($20.5M cash + Repligen stock) plus up to $8.75M milestones and a capped royalty up to $2.15M.

The significant overlap of Refine's customer base with our own will support a global buildout of our commercial infrastructure.Walter C. Herlihy — Ph.D., President and CEO, Repligen

Acquisition of Atoll GmbH & Co. KG, maker of the MediaScout family of pre-packed chromatography products, broadening Repligen's portfolio and expanding its customer base, particularly complementing the OPUS pre-packed disposable chromatography column line. ~$22.5 million total upfront ($9.1M cash + Repligen stock) plus a potential EUR 1.0M payment.

Atoll's MediaScout family of products is a market and technology fit for Repligen that complements our growing OPUS product line of pre-packed disposable chromatography columns.Tony J. Hunt — President and Chief Executive Officer, Repligen

The MediaScout product line has experienced accelerating demand over the last few years. The synergies with Repligen, and OPUS in particular, are clear.Martin Reuter — Managing Director, Atoll

Acquisition of TangenX Technology Corporation, adding innovative single-use, flat-sheet tangential flow filtration (TFF) cassettes (the SIUS line) to Repligen's filtration portfolio. EUR 37.0 million (~USD 39.0 million), all cash.

Our commitment to delivering high value and flexible TFF solutions to the bioprocessing industry is closely aligned with Repligen's focus on technological innovation.John Connors — President, TangenX

Acquisition of Spectrum, Inc., a maker of hollow-fiber (HF) filtration products and KrosFlo TFF systems plus the Spectra/Por dialysis line, in a transaction Repligen called pivotal. Spectrum recorded revenue of $40.2 million in 2016. The deal substantially expanded Repligen's filtration franchise and global commercial footprint. ~$359 million ($120M cash + ~$239M in Repligen stock).

This is a pivotal transaction for Repligen that meets all of our acquisition criteria and is a major step forward in building Repligen as a global leader in bioprocessing.Tony J. Hunt — President and CEO, Repligen

Spectrum has developed world-class products delivered with first-class customer service. Repligen has a proven track record of unlocking additional value and accelerating growth.Roy Eddleman — Chairman and CEO, Spectrum

Acquisition of privately held C Technologies, Inc., maker of the SoloVPE and FlowVPE Slope Spectroscopy systems for real-time protein concentration measurement, establishing Repligen's Process Analytics franchise. Projected to contribute ~$16-$17 million in revenue. ~$240 million ($192M cash + $48M in Repligen stock).

The addition of C Technologies is a major step forward in building out a Process Analytics franchise for Repligen. We look forward to further developing the core Slope Spectroscopy technology for real-time bioprocess applications.Tony J. Hunt — President and CEO, Repligen

We are very proud of the progress and impact we have made in biopharma over the past decade. Our culture of technology innovation and customer centricity is what differentiates us.Craig Harrison — President and CEO, C Technologies

Acquisition of Engineered Molding Technology LLC, a manufacturer of single-use silicone assemblies and components used in the manufacture of biologic drugs. EMT expands Repligen's ProConnex flow-path line and streamlines its ATF supply chain. Effective July 11, 2021, EMT was absorbed into Repligen via short-form merger.

The acquisition of EMT expands our line of single-use ProConnex flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale.Tony J. Hunt — President and CEO, Repligen

Over the last ten years, EMT has grown to become a key player in the supply of extruded and molded silicone products into the bioprocessing industry.Michael Pandori — co-founder, Engineered Molding Technology

Acquisition of Non-Metallic Solutions, Inc., a manufacturer of fabricated plastics, custom containers and related assemblies and components used in manufacturing biologic drugs. NMS's fluid-management products complement and expand Repligen's single-use flow paths and durable-plastics portfolio.

NMS, which is headquartered in Auburn, Massachusetts, is a manufacturer of fabricated plastics, custom containers, and related assemblies and components used in the manufacturing of biologic drugs. NMS's fluid management products complement and expand Repligen's portfolio.Repligen FY22 10-K — 2020 Acquisitions note

Acquisition of ARTeSYN Biosolutions, a maker of gold-standard single-use downstream bioprocessing systems including automated chromatography and filtration systems with unique single-use flow-path designs. The deal advanced Repligen's Systems strategy in Filtration and Chromatography, complementing TangenX flat-sheet cassettes and OPUS pre-packed columns. ARTeSYN was projected to generate ~$30 million in revenue. ~$200 million (~$130M cash + ~$70M in Repligen stock).

The addition of ARTeSYN Biosolutions and Non-Metallic Solutions further strengthens our Systems offering. The ARTeSYN portfolio expands on the market success of our hollow-fiber and flat-sheet products.Tony J. Hunt — President and CEO, Repligen

We have made tremendous progress over the last four years as we introduced automated, highly efficient chromatography and filtration systems with unique flow path designs.Michael Gagne — Founder and CXO, ARTeSYN Biosolutions

Acquisition of Polymem S.A., a French manufacturer of hollow-fiber membranes, membrane modules and systems for industrial and bioprocessing applications. Polymem expanded Repligen's HF membrane and module production capacity, added core R&D and engineering expertise in HF technology, and established a Europe-based HF manufacturing center of excellence complementing the Spectrum HF / KrosFlo product line. ~$47 million, all cash.

With our acquisition of Polymem S.A. on July 1, 2021, we further expanded our HF membrane and module production capabilities and added core R&D, engineering and production expertise in HF technology. The acquisition of Polymem accelerated our HF manufacturing buildout and added a Europe-based HF manufacturing center of excellence.Repligen FY22 10-K — Item 1 Business / Acquisitions note

Acquisition of privately held Avitide, Inc., a market leader in affinity ligand discovery and development, moving Repligen into affinity resin solutions for gene therapy and other emerging modalities. The deal strengthened Repligen's Proteins business and complemented its established partnership with Navigo GmbH. Avitide was expected to contribute ~$10 million in revenue in 2022. ~$150 million ($75M cash + $75M in Repligen stock).

The addition of Avitide is a major step forward in building out our Proteins business and in particular our affinity ligand discovery engine. This acquisition builds off the excellent partnership we have already established with Navigo GmbH and really strengthens and expands our ligand discovery and development capabilities.Tony J. Hunt — President and CEO, Repligen

We have made tremendous progress in affinity ligand and chromatography development over the past decade. Repligen is the ideal partner to drive the expanded development of affinity resins for gene therapy and other emerging modalities.Kevin Isett — President and CEO, Avitide

Acquisition of Newton T&M Corp (NTM), the parent of BioFlex Solutions, LLC, including BioFlex's commercialization arm and NTM's manufacturing operations. Both companies, headquartered in Newton, New Jersey, manufacture and commercialize single-use fluid-management products, expanding Repligen's single-use flow-path and assembly capabilities. ~$31.6 million total consideration.

NTM, which is headquartered in Newton, New Jersey, is the parent company of BioFlex and focuses on manufacturing of products, while BioFlex, also headquartered in Newton, New Jersey, commercializes single-use fluid management products.Repligen FY22 10-K — 2021 Acquisitions note

Acquisition of all outstanding equity interests in FlexBiosys, Inc., a custom designer and manufacturer of single-use bioprocessing products, strengthening Repligen's fluid-management portfolio. Earnout periods run from Jan 1, 2023 through Dec 31, 2024. ~$41.0 million total ($29.0M cash + Repligen stock, plus earnouts).

On April 17, 2023, we completed the acquisition of all of the outstanding equity interests in FlexBiosys. FlexBiosys, which is headquartered in Branchburg, New Jersey, offers expert design of custom manufacturing of single-use bioprocessing products.Repligen FY23 10-K — 2023 Acquisitions note

Acquisition of privately held Metenova AB of Molndal, Sweden, adding market-leading magnetic mixing and drive-train technology for upstream and downstream bioprocess applications, including the single-use MixOne platform. Metenova was projected to generate $24-$25 million of revenue in fiscal 2023. ~$172.6 million total ($164.5M cash + Repligen stock, plus ~$10M earnout).

The addition of Metenova further strengthens our Fluid Management portfolio, with a product line that expands on the market success of our systems and fluid management.Tony J. Hunt — President and Chief Executive Officer, Repligen

Acquisition of Tantti Laboratory Inc. of Taoyuan City, Taiwan, developer of a portfolio of macroporous chromatography beads (including Dulocore base bead technology) to optimize purification of new modalities such as viral vectors, viruses and nucleic acids. The technology underpins Repligen's HiPer base beads and AVIPure resin extensions. Tantti contributed $78.1 million of total assets and no revenue as of Dec 31, 2024. ~$54.8 million cash (net of cash acquired), plus up to $54.5 million earnout.

With our acquisition of Tantti Laboratory Inc. on December 2, 2024, we expect to accelerate our expansion into new modality markets with unique, scalable purification solutions for these larger molecule biologics.Repligen FY24 10-K — Item 1 Business / 2024 Acquisition note

Acquisition of 908 Devices Inc.'s desktop portfolio of four bioprocessing process analytical technology (PAT) devices, together with related facilities, employees, equipment and lease obligations in North Carolina and Braunschweig, Germany. The deal added upstream PAT solutions, complementing the downstream PAT capability gained from C Technologies in 2019, and was rebranded under the PATsmart line in 2025. ~$70.3 million total consideration.

We added to our Analytics portfolio in 2025 through the acquisition of 908 Devices Inc.'s bioprocessing portfolio, which brought upstream PAT solutions. In 2025, we rebranded our Analytics offerings to PATsmart.Repligen FY25 10-K — Item 1 Business